91ÊÓƵרÇø

ËæÐÔËùÓûµÚ¶þ¼¾01È«¼¯ÍêÕû°æÃâ·ÑÔÚÏß¹Û¿´³åµçÊÓ¾ç...¡¶Ê§¿Ø»å°ù¾±±¹±ð²ÔµÚÒ»¼¾°Ù¶ÈÍøÅÌ¡·ÈÕº«µçÓ°ÔÚÏß¹Û¿´...

ÔÚͶËߵĹý³ÌÖУ¬ÎÒÏêϸµØÃèÊöÁËÕâ´ÎÂÃÐÐÖеÄÖÖÖÖÎÊÌ⣬ÌṩÁËÏà¹ØµÄÖ¤¾ÝºÍÕÕƬ¡£Ïà¹Ø²¿Ãűíʾ»á¶Ô´Ë½øÐе÷²éºÍ´¦Àí¡£

2024Äê12ÔÂ26ÈÕ£¬13.¡°½ðÎÑÒøÎѲ»Èç×Ô¼ºµÄ¹·ÎÑ¡±£¬²»ÒªÌýÐÅÈκÎÈ˵Ļ°Âôµô×Ô¼ºµÄ·¿×Ó¡£·¿×Ó²»½öÊÇ×îºóµÄ¹éËÞ£¬Ò²ÊÇ¿ÉÒÔ×ÔÁ¢Éú»îµÄµ×Æø¡£Âôµô·¿×ÓµÄÒ»°ã¶¼»áºó»Ú¡£

ËæÐÔËùÓûµÚ¶þ¼¾01È«¼¯ÍêÕû°æÃâ·ÑÔÚÏß¹Û¿´³åµçÊÓ¾ç...¡¶Ê§¿Ø»å°ù¾±±¹±ð²ÔµÚÒ»¼¾°Ù¶ÈÍøÅÌ¡·ÈÕº«µçÓ°ÔÚÏß¹Û¿´...

Çà½ÅÂ鼦:´º½ÚÆÚ¼äÇà½ÅÂ鼦»îÇÝÊг¡Õý³£½»Ò×¼Û¸ñ½Ï´º½ÚÇ°Ï»¬0.30-0.50Ôª/½ï½Úºóʵ¼Ê³É½»¼Û¸ñÔÚ5.20-5.70Ôª/½ïÊг¡×ß»õƽÎÈ´ó¹æ¸ñ¼¦¹©Ó¦Á¿ÒÀ¾ÉÆ«½ôÖÐС¹æ¸ñ¼¦Ô´Õý³£Êг¡³É½»Æ½µ­ÍÀÔ×¹«Ë¾Â½Ðø¿ª¹¤Â鼦Êг¡ÉÔÓÐÆðÉ«µ«ÕûÌå¼Û¸ñÆ«ÈõÔËÐÐÂ鼦ÃçÊг¡»ù±¾Îȶ¨µ±Ç°²¹À¸²»¶àµ«ÊǼ¦Ã繩ӦÁ¿Ïà¶ÔƽÎÈÂ鼦Ãç¼Û¸ñ¸ßµÍ²»Ò»¼Û¸ñÔÚ1.80-3.20Ôª/Óð²»µÈÖÖÇݹ«Ë¾ÅÅÃç¼Æ»®Ïà¶ÔÎȶ¨Êг¡¿ªÊ¼½»Ò×

ËäÈ»¹¤×÷Îȶ¨£¬µ«ÔÂн²»¹ýǧ°Ñ¿é¡£¼´±ãÊ¡³Ô¼óÓã¬Ò»±²×ÓÒ²ÄÑÒÔ»ýÔÜÈç´Ë¾Þ¶îµÄ´æ¿î¡£¸üÁîÈ˲»½âµÄÊÇ£¬ÎªºÎÕâ±ÊÇ®´æÁ˶þÊ®¶àÄ궼ûÓÐÈ¡³ö£¿¢Ú¼ÓÓÍ63.9Éý£¬·ÑÓÃ510Ôª

±ô¾±²¹²Ô²µ°ù±ð²Ô²µ±ð²Ô²ú±ð²Ô²ú³Ü²õ³ó¾±²â¾±²µ±ð²õ¾±³æ¾±²¹²Ô²µ³¦±ð²Ô²µ³¾¾±²¹²Ô»å±ð°ù±ð²Ô¡£2024°ì³Ü²¹²Ô´Ú³Ü³Ù±ð±ô¾±±ð³¾²¹³ú²¹¾±³¦³ó³Ü²¹²Ô³¦³ó±ð²Ô²µÂá¾±²Ô²µ»å¾±²¹²Ô²â³Ü±ð²â±ð³§±«³Õ»å±ðÂá¾±³¦³ó³Ü²õ³ó²¹²Ô²µ£¬°ù´Ç²Ô²µ°ù³Ü±ô¾±²¹´Ç²µ±ð²Ô²µ»å³Ü´Ç³æ¾±²¹²Ô»å²¹¾±°ì±ðÂá¾±²â³Ü²¹²Ô²õ³Ü£¬·É³Ü±ô³Ü²Ô²õ³ó¾±²â³Ü±ð²â±ð³æ¾±²Ô²µ²Ô±ð²Ô²µ³ó³Ü²¹²Ô²õ³ó¾±²õ³ó³Ü²õ³ó¾±³æ¾±²Ô²µ£¬»å³Ü»å±ð»å²¹´Ç±ô¾±²¹´Ç»å²¹´Ú³Ü³Ù¾±²õ³ó±ð²Ô²µ¡£³ú³ó±ð°ì³Ü²¹²Ô³¦³ó±ð³æ¾±²Ô²µ·É³Ü²â¾±Âá¾±²¹²Ô²µ³¦³ó±ð²Ô²µ·É±ð¾±·É±ð¾±±ô²¹¾±²õ³ó¾±³¦³ó²¹²Ô²µ²õ³ó²¹²Ô²µ»å±ð²â¾±°ì³Ü²¹²Ô²õ³ó¾±±ô¾±Âá¾±²Ô²µ³ú³ó±ð²Ô²µ³ú³ó±ð£¬·É±ð¾±³æ¾±²¹´Ç´Ú±ð¾±³ú³ó±ð»å²¹¾±±ô²¹¾±²µ±ð²Ô²µÂá¾±²¹Âá¾±³ú³ó¾±»å±ðÂá¾±²¹²õ³ó¾±³Ù¾±²â²¹²Ô¡£

ÔÚ(´Ü²¹¾±)Ìô(°Õ¾±²¹´Ç)Ñ¡(³Ý³Ü²¹²Ô)Å£(±·¾±³Ü)Èâ(¸é´Ç³Ü)ʱ(³§³ó¾±)£¬ÎÒ(°Â´Ç)ÃÇ(²Ñ±ð²Ô)Ðè(³Ý³Ü)Òª(³Û²¹´Ç)ÀÎ(³¢²¹´Ç)¼Ç(´³¾±)¡°3²»(µþ³Ü)Âò(²Ñ²¹¾±)¡±Ô­(³Û³Ü²¹²Ô)Ôò(´Ü±ð)£º²»(µþ³Ü)Âò(²Ñ²¹¾±)×¢(´Ü³ó³Ü)Ë®(³§³ó³Ü¾±)Èâ(¸é´Ç³Ü)¡¢²»(µþ³Ü)Âò(²Ñ²¹¾±)ÑÕ(³Û²¹²Ô)É«(³§±ð)·¢(¹ó²¹)ºÚ(±á±ð¾±)µÄ(¶Ù±ð)Èâ(¸é´Ç³Ü)¡¢²»(µþ³Ü)Âò(²Ñ²¹¾±)Æø(²Ï¾±)ζ(°Â±ð¾±)Òì(³Û¾±)³£(°ä³ó²¹²Ô²µ)µÄ(¶Ù±ð)Èâ(¸é´Ç³Ü)¡£½Ó(´³¾±±ð)ÏÂ(³Ý¾±²¹)À´(³¢²¹¾±)£¬ÎÒ(°Â´Ç)½«(´³¾±²¹²Ô²µ)´Ó(°ä´Ç²Ô²µ)Å£(±·¾±³Ü)Èâ(¸é´Ç³Ü)µÄ(¶Ù±ð)²¿(µþ³Ü)λ(°Â±ð¾±)¡¢ÑÕ(³Û²¹²Ô)É«(³§±ð)¡¢Æø(²Ï¾±)ζ(°Â±ð¾±)µÈ(¶Ù±ð²Ô²µ)·½(¹ó²¹²Ô²µ)Ãæ(²Ñ¾±²¹²Ô)£¬Îª(°Â±ð¾±)´ó(¶Ù²¹)¼Ò(´³¾±²¹)Ïê(³Ý¾±²¹²Ô²µ)ϸ(³Ý¾±)½é(´³¾±±ð)ÉÜ(³§³ó²¹´Ç)Èç(¸é³Ü)ºÎ(±á±ð)Ìô(°Õ¾±²¹´Ç)Ñ¡(³Ý³Ü²¹²Ô)µ½(¶Ù²¹´Ç)ÓÅ(³Û´Ç³Ü)ÖÊ(´Ü³ó¾±)µÄ(¶Ù±ð)Å£(±·¾±³Ü)Èâ(¸é´Ç³Ü)¡£

congdaodejiaodulaikan£¬wanwumeiyouchabie¡£ruhequfenfeidianxingCMLyuqitagusuizengzhixingzhongliuyuanchuang2020-09-12 17:53¡¤yimaitongxueyekezuozhe£ºlanjingxiaohubenwenweizuozheshouquanyimaitongfabu£¬weijingshouquanqingwuzhuanzai¡£feidianxingmanxingsuixibaixuebing(aCML)£¬BCR-ABL1(£­)£¬shiyizhonghanjiandexueyeexingzhongliu£¬shuyuWHOgusuizhongliufenleizhongdegusuizengshengyichang/gusuizengzhixingzhongliu(MDS/MPN)¡£aCMLzuichubeimingmingwei¡°feidianxing¡±xingshidemanxingsuixibaixuebing(CML)£¬jishinianlaiaCMLdezhenduanbiaozhunfashengliaoxianzhubianhua¡£raner£¬aCMLdezhenduanquefatezhengxing£¬duiqifenzijiyintupuderiyiliaojieyouzhuyuqufenaCMLyuqitaMDS/MPNheMPNs£¬yibianzaoqiqidongzhiliaohegaishanyuhou¡£aCMLdelinchuanghexingtaibiaoxingaCMLhuanzhebiaoxianchugusuizengshengtezheng£¬baokuobaixibaozengduohepizhongda£¬kebanyoupinxuehexuexiaobanjianshao¡£WBCjishu¡Ý13¡Á109/L¡£waizhouxuezhongcunzaizhishao10%deweichengshulixibao£¨baokuozaoyoulixibao¡¢zhongyoulixibaohewanyoulixibao£©£¬yizhongdulixibaoshengchengzhangaiweitezheng¡£bucunzaidanhexibaozengduo£¨waizhouxuedanhexibao2%£©¡£xibaohuaxueranse£¬rufeiteyixingzuomei(NSE)youzhuyuzaiyinanbinglizhongjiancedanhexibao¡£lingyigegengzhuguandexingtaixuequbieshiaCMLcunzaigengyanzhongdelixibaofayubuliang£¬jinguanquefapinggufayubuliangyanzhongchengdudejutizhinan¡£xuyaojinxingtieranseyipaichubanyouhuanxingtieliyouxibaohexuexiaobanzengduodeMDS/MPN-RS-T¡£zaiyizengzhitezhengweizhu£¬qieyizhongxinglixibaoweizhudehuanzhezhong£¬CSF3RtubianyingqianglietishiCNL¡£qufenaCMLyuMDS/MPN-Ujiaoweikunnan¡£aCMLhuanzhedezhongweiWBCjishuxianzhushenggao£¬danfeijueduitezheng¡£chixuxingdanhexibaozengduotishiCMML¡£TET2+SRSF2tubianduiCMMLjuyouxiangduiteyixing£¬jinguanliangzhezaiaCMLzhongjunkejian¡£yizhongxindeaCMLzhenduanliuchengxiaojieyouyufabinglvdi¡¢zhenduanbiaozhunbuduangengxinhequefafenziyichuanxuedelijie£¬feidianxingmanxingsuixibaixuebingyizhishiyizhongnanyizhenduandeMDS/MPN¡£suizhuoduijiyinzudashujudebuduanwajue£¬yifaxianSETBP1heETNK1defanfutubianduiaCMLyoutishizuoyong£¬keyijieheshiyanshihexingtaixuejieguolaiqufenaCMLheqitafeichengyinxinggusuizengzhixingzhongliu¡£ranertubiandetongshifashengshifouhuigaibianaCMLdejibingbiaoxinghezhiliaofanyingshangbumingque¡£cankaowenxian£º1. Orazi A, Bennett JM, Bain BJ, et al. Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2017. pp. 87¨C89.2. Kantarjian HM, Keating MJ, Walters RS, et al. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer 1986; 58:2023¨C2030.3. Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 2001; 19:2915¨C2926.4. Giri S, Pathak R, Martin MG, Bhatt VR. Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database. Ther Adv Hematol 2015; 6:308¨C312.5. Sadigh S, Hasserjian RP, Hobbs G. Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms. Curr Opin Hematol. 2020;27(2):122-127.6. Itonaga H, Ota S, Ikeda T, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: a retrospective nationwide study in Japan. Leuk Res 2018; 75:50¨C57.7. Meggendorfer M, Haferlach T, Alpermann T, et al. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. Haematologica 2014; 99:e246.8. Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 2014; 123:2645 -2651.9. Patnaik MM, Barraco D, Lasho TL, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 2017; 92:542¨C548.10. Schwartz LC, Mascarenhas J. Current and evolving understanding of atypical chronic myeloid leukemia. Blood Rev 2019; 33:74¨C81.11. Faisal M, Stark H, Busche G, € et al. Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia. Cancer Med 2019; 8:742¨C750.12. Zhang H, Wilmot B, Bottomly D, et al. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood 2019; 134:867¨C879.13. Hasserjian RP. Illuminating neutrophilic myeloid neoplasms. Blood 2019; 134:846¨C848.14. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002; 107:113¨C122.15. Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 2014; 123:3574¨C3577.16. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012; 120: 3080¨C3088.

±È(Bi)ÑÇ(Ya)µÏ(Di)°Ù(Bai)Íò(Wan)¼¶(Ji)ÐÂ(Xin)ÄÜ(Neng)Ô´(Yuan)Æì(Qi)½¢(Jian)½Î(Jiao)³µ(Che)£ºÑö(Yang)Íû(Wang)U7ʵ(Shi)³µ(Che)ÆØ(Pu)¹â(Guang)2024-01-11 16:41¡¤Ã¿(Mei)ÈÕ(Ri)³µ(Che)ÊÐ(Shi)¾«(Jing)Ñ¡(Xuan)¿ì(Kuai)¿Æ(Ke)¼¼(Ji)1ÔÂ(Yue)11ÈÕ(Ri)Ïû(Xiao)Ï¢(Xi)£¬×ò(Zuo)ÈÕ(Ri)Ñö(Yang)Íû(Wang)Æû(Qi)³µ(Che)µÚ(Di)Èý(San)¿î(Kuan)³µ(Che)ÐÍ(Xing)U7¹Ù(Guan)ͼ(Tu)·¢(Fa)²¼(Bu)ºó(Hou)£¬Òý(Yin)Æð(Qi)ÁË(Liao)¹Ù(Guan)¹ã(Guang)·º(Fan)ÌÖ(Tao)ÂÛ(Lun)£¬Õù(Zheng)Òé(Yi)ÆÄ(Po)´ó(Da)£¬½ñ(Jin)ÈÕ(Ri)£¬Ñö(Yang)Íû(Wang)Æû(Qi)³µ(Che)Ö±(Zhi)½Ó(Jie)¹«(Gong)²¼(Bu)ÁË(Liao)¸Ã(Gai)³µ(Che)µÄ(De)ʵ(Shi)ÅÄ(Pai)ͼ(Tu)¡£¾Ý(Ju)Ϥ(Xi)£¬Æä(Qi)¶¨(Ding)λ(Wei)ÓÚ(Yu)°Ù(Bai)Íò(Wan)¼¶(Ji)Æì(Qi)½¢(Jian)ÐÂ(Xin)ÄÜ(Neng)Ô´(Yuan)½Î(Jiao)³µ(Che)£¬½á(Jie)ºÏ(He)¹Ù(Guan)ͼ(Tu)¿É(Ke)Öª(Zhi)£¬Ç°(Qian)Á³(Lian)²É(Cai)ÓÃ(Yong)ÁË(Liao)¼Ò(Jia)×å(Zu)»¯(Hua)µÄ(De)Éè(She)¼Æ(Ji)Óï(Yu)ÑÔ(Yan)£¬Ãû(Ming)Ϊ(Wei)¡°Ê±(Shi)¿Õ(Kong)Ö®(Zhi)ÃÅ(Men)¡±£¬Ôì(Zao)ÐÍ(Xing)±ð(Bie)ÖÂ(Zhi)µÄ(De)C×Ö(Zi)ÐÎ(Xing)µÆ(Deng)×é(Zu)Åä(Pei)ºÏ(He)ÏÂ(Xia)·½(Fang)¹á(Guan)´©(Chuan)ʽ(Shi)½ø(Jin)Æø(Qi)¿Ú(Kou)£¬¿´(Kan)ÉÏ(Shang)È¥(Qu)Ê®(Shi)·Ö(Fen)¾ß(Ju)ÓÐ(You)±æ(Bian)ʶ(Shi)¡£Í¬(Tong)ʱ(Shi)£¬¸Ã(Gai)³µ(Che)²É(Cai)ÓÃ(Yong)ÐÂ(Xin)ÄÜ(Neng)Ô´(Yuan)³µ(Che)¹ß(Guan)ÓÃ(Yong)µÄ(De)·â(Feng)±Õ(Bi)ʽ(Shi)Ç°(Qian)¸ñ(Ge)Õ¤(Zha)£¬Ç°(Qian)²Õ(Cang)¸Ç(Gai)²¢(Bing)Éè(She)¼Æ(Ji)¶à(Duo)Ìõ(Tiao)¡(Long)Æð(Qi)µÄ(De)½î(Jin)Ïß(Xian)½ø(Jin)ÐÐ(Xing)µã(Dian)׺(Zhui)£¬ÔË(Yun)¶¯(Dong)Æø(Qi)Ï¢(Xi)Ũ(Nong)ºñ(Hou)¡£´Ë(Ci)´Î(Ci)·Å(Fang)³ö(Chu)µÄ(De)ʵ(Shi)ÅÄ(Pai)ͼ(Tu)Àï(Li)£¬Ñö(Yang)Íû(Wang)U7²à(Ce)Ãæ(Mian)¿´(Kan)È¥(Qu)·Ç(Fei)³£(Chang)ÐÞ(Xiu)³¤(Chang)£¬Ä¿(Mu)²â(Ce)Æä(Qi)³µ(Che)³¤(Chang)»á(Hui)´ï(Da)µ½(Dao)5.2Ã×(Mi)£¬Åä(Pei)ÓÐ(You)Òþ(Yin)²Ø(Cang)ʽ(Shi)ÃÅ(Men)°Ñ(Ba)ÊÖ(Shou)£¬´°(Chuang)»§(Hu)ËÄ(Si)ÖÜ(Zhou)»¹(Huan)¸¨(Fu)Ö®(Zhi)ÒÔ(Yi)¶Æ(Du)¸õ(Ge)×°(Zhuang)ÊÎ(Shi)¼þ(Jian)£¬¶ø(Er)´ó(Da)±ý(Bing)ʽ(Shi)ÂÖ(Lun)Ȧ(Quan)Ò²(Ye)½ø(Jin)Ò»(Yi)²½(Bu)ºæ(Hong)ÍÐ(Tuo)ÁË(Liao)Æä(Qi)ºÀ(Hao)»ª(Hua)¸Ð(Gan)¡£³µ(Che)¶¥(Ding)²É(Cai)ÓÃ(Yong)ÁË(Liao)Áï(Liu)±³(Bei)µÄ(De)Éè(She)¼Æ(Ji)£¬µ«(Dan)²¢(Bing)·Ç(Fei)ÊÇ(Shi)GT½Î(Jiao)³µ(Che)µÄ(De)·ç(Feng)¸ñ(Ge)£¬Òò(Yin)´Ë(Ci)Æä(Qi)β(Wei)ÃÅ(Men)Ϊ(Wei)´«(Chuan)ͳ(Tong)Ñù(Yang)ʽ(Shi)£¬¶ø(Er)·Ç(Fei)ÏÆ(Xian)±³(Bei)ʽ(Shi)£¬Î²(Wei)²¿(Bu)Éè(She)¼Æ(Ji)Õû(Zheng)Ìå(Ti)±È(Bi)½Ï(Jiao)Ô²(Yuan)Èó(Run)£¬µ«(Dan)ͬ(Tong)ʱ(Shi)²ã(Ceng)´Î(Ci)·Ö(Fen)Ã÷(Ming)£¬Åä(Pei)ÓÐ(You)¹á(Guan)´©(Chuan)ʽ(Shi)β(Wei)µÆ(Deng)£¬ÖÐ(Zhong)¼ä(Jian)λ(Wei)ÖÃ(Zhi)Ôò(Ze)ÊÇ(Shi)Ñö(Yang)Íû(Wang)µÄ(De)Æ·(Pin)ÅÆ(Pai)Logo¡£¶¯(Dong)Á¦(Li)·½(Fang)Ãæ(Mian)ÔÝ(Zan)δ(Wei)ÓÐ(You)¾ß(Ju)Ìå(Ti)²Î(Can)Êý(Shu)ÐÅ(Xin)Ï¢(Xi)£¬²»(Bu)¹ý(Guo)¹Ù(Guan)·½(Fang)³Æ(Cheng)Æä(Qi)Åä(Pei)±¸(Bei)Ò×(Yi)ËÄ(Si)·½(Fang)¼¼(Ji)Êõ(Shu)£¬Âí(Ma)Á¦(Li)³¬(Chao)ǧ(Qian)Æ¥(Pi)£¬ÄÇ(Na)ô(Me)´ó(Da)¸Å(Gai)ÂÊ(Lv)Ò²(Ye)»á(Hui)´î(Da)ÔØ(Zai)ËÄ(Si)µç(Dian)»ú(Ji)£¬Ëù(Suo)ÒÔ(Yi)Ñö(Yang)Íû(Wang)U8ºÍ(He)U9Ëù(Suo)¾ß(Ju)±¸(Bei)µÄ(De)Ô­(Yuan)µØ(Di)µô(Diao)Í·(Tou)µÈ(Deng)¹¦(Gong)ÄÜ(Neng)£¬U7´ó(Da)¸Å(Gai)ÂÊ(Lv)ͬ(Tong)Ñù(Yang)¿É(Ke)ʵ(Shi)ÏÖ(Xian)¡£

¶¯Á¦·½Ã棬ÐǹâS¾ÝϤ½«Òª´îÔØÁéϬ¶¯Á¦ÓëÉñÁ¶µç³Ø£¬²å»ì°æ´îÔØ1.5L×ÔÎü·¢¶¯»ú£¬×î´ó¹¦ÂÊ78kW£¬µç»ú¹¦ÂÊÉÐδÉ걨£¬µ«¿ÉÒÔ²ÒÄ¿ÏÖÔÚµÄÎåÁâÐǹ⣬µç»ú×î´ó¹¦ÂÊÊÇ150kW£¬×÷Ϊ¼ÒÓóµÒ²Êǹ»Óõġ£¶ø´¿µç°æµÄµç»ú×î´ó¹¦ÂÊΪ150kW£¬²ÉÓõ¥µç»úÉ趨¡£Ó¦¸Ã˵£¬ÎåÁâÐǹâSÒ²ºÜÖµµÃÆÚ´ý£¬ÐÔ¼Û±ÈûµÃÌô£¬¾Í¿´¿Æ¼¼ÅäÖÃÉÏ»á¸øµ½Ê²Ã´²ã¼¶ÁË¡£¶îÍ·´²µÄ¿Õ¼ä±íÏÖÁ½³µÒ»Ö£¬³ß´çͬÑùÊÇ2.04¡Á1.5Ã×£¬ÓéÀÖÉèʩҲͬÑù²ÉÓÃÁËͶӰĻ²¼ÐÎʽ¡£ËæÐÔËùÓûµÚ¶þ¼¾01È«¼¯ÍêÕû°æÃâ·ÑÔÚÏß¹Û¿´³åµçÊÓ¾ç...¡¶Ê§¿Ø»å°ù¾±±¹±ð²ÔµÚÒ»¼¾°Ù¶ÈÍøÅÌ¡·ÈÕº«µçÓ°ÔÚÏß¹Û¿´...

°Í¿ËÀ³ÒøÐÐÃÀ¹úÀûÂʲßÂÔÖ÷¹ÜAnshul PradhanдµÀ£º²ÆÕþ×´¿öµÄ¶ñ»¯ÒÔ¼°Ï൱κ͵IJÆÕþÖ§³öÏ÷¼õ±íÃ÷¼´½«µ½À´µÄÃÀÕ®¹©Ó¦·ºÀĽ«²»½ö½ö¾ÖÏÞÓÚ¶ÌÆÚÃÀ¹ú¹úÕ®ÃÀ¹ú²ÆÕþ²¿ºÜ¿ì¾ÍÐèÒª´ó·ùÔö¼Ó²»Í¬ÆÚÏÞ¹úÕ®µÄÅÄÂô¹æÄ£ÎÒÃÇÈÏΪÀûÂÊÊг¡¹ýÓÚ×ÔÂú

·¢²¼ÓÚ£ºÆ½ÏçÏØ
ÉùÃ÷£º¸ÃÎĹ۵ã½ö´ú±í×÷Õß±¾ÈË£¬ËѺüºÅϵÐÅÏ¢·¢²¼Æ½Ì¨£¬ËѺü½öÌṩÐÅÏ¢´æ´¢¿Õ¼ä·þÎñ¡£
Òâ¼û·´À¡ ºÏ×÷

Copyright ? 2023 Sohu All Rights Reserved

ËѺü¹«Ë¾ °æȨËùÓÐ